Pfizer, Inc. (PFE) Stock Analysis
Healthcare · Drug Manufacturers - General · NYSE
Pfizer, Inc. (PFE) posted $62.58B in revenue for fiscal 2025 (down 1.6% year over year), at a 12.4% net margin, and has compounded revenue about 8.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Pfizer, Inc.
Pfizer, Inc. has grown revenue from $52.82B to $62.58B over the last 10 fiscal years, compounding about 8.5% a year. The most recent year was down 1.6%, so growth has cooled from its longer-run pace.
Net margin sits at 12.4% on a 74.3% gross margin. It carries about $64.80B of total debt.
The one thing worth a second look in the filings is heavy debt load.
Synthesised from Pfizer, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Pfizer, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B |
| Gross profit | $40.50B | $41.32B | $31.84B | $32.85B | $33.17B | $50.47B | $66.83B | $34.60B | $45.78B | $46.51B |
| Net income | $7.21B | $21.31B | $11.15B | $16.03B | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| Net margin | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
Source: Pfizer, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
Pfizer, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $67792M is 5.8× last year's operating cash flow — it would take years of cash flow to clear.
- Net margin shrinkingNet margin fell from 31.0% to 12.4% over ~3 years — profitability is compressing.
Explore 19 years of Pfizer, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PFE in your portfolio →
Pfizer, Inc. financial history by metric
Compare Pfizer, Inc. with peers
About Pfizer, Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer, Inc. — frequently asked questions
What is Pfizer, Inc.'s revenue?
Pfizer, Inc. (PFE) reported revenue of $62.58B for fiscal year 2025, down 1.6% from the prior year, according to its SEC filings.
Is Pfizer, Inc. profitable?
Yes. PFE earned net income of $7.77B in fiscal 2025, a net margin of 12.4%.
What is PFE's P/E ratio?
Pfizer, Inc. trades at a price-to-earnings ratio of about 19.1 based on the latest data in our nightly-refreshed cache.
How fast is Pfizer, Inc. growing?
PFE's revenue grew at roughly 8.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Pfizer, Inc. have?
As of fiscal year 2025, PFE carried roughly $64.80B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Pfizer, Inc.'s gross margin?
PFE's gross margin was 74.3% in fiscal 2025 — gross profit of $46.51B on revenue of $62.58B.
What is Pfizer, Inc.'s market cap?
Pfizer, Inc. (PFE) has a market capitalization of about $0, based on the latest data in our nightly-refreshed cache.
When does Pfizer, Inc.'s fiscal year end?
PFE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Pfizer, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.